Format

Send to

Choose Destination
See comment in PubMed Commons below
J Epidemiol Community Health. 1992 Dec;46(6):587-94.

Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.

Author information

  • 1Department of Data Analysis, Ministry of Health, Jerusalem, Israel.

Abstract

STUDY OBJECTIVE:

The aim was to estimate the costs and benefits of a nationwide neonatal vaccination campaign against hepatitis B in Israel for the 1990-2034 period.

DESIGN:

Using morbidity, mortality, utilisation, and cost data from Israeli and international sources, a spreadsheet model was constructed to carry out the cost-benefit analysis.

SETTING:

The entire State of Israel, an area of intermediate endemicity.

PARTICIPANTS:

The population of Israel from 1990-2034.

MAIN RESULTS:

A policy of immunising all Israeli neonates would, for a cost of $13.8 million, reduce the number of cases of hepatitis B during the 1990-2035 period in the cohort from 359,000 to 166,000 and save the nation around $21.5 million in health resources alone, $16.6 million in averted work absences, and a further $0.6 million in averted premature mortality costs. Even when the savings to the health services ($0.6 million) arising from the reduction in hepatocellular carcinoma are excluded, the direct benefit to cost ratio is 1.51/1, still in excess of unity.

CONCLUSIONS:

The decision to adopt a nationwide neonatal inoculation policy, starting in January 1992, appears to be not only medically but also economically justifiable.

PMID:
1494073
PMCID:
PMC1059674
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk